Russian company develops new leukemia drug candidate
25 Apr '14
Fusion Pharma, a biotech developer at the Skolkovo innovation hub outside Moscow, has come up with a new leukemia drug candidate and is gearing up for clinical trials, the Skolkovo Foundation website announced.
“We will do our best to launch the clinical trials of the PF-114 candidate as soon as possible,” the Foundation cited a statement by Germes Chilov, Ph.D. in chemistry, the CEO of Fusion Pharma.
The new drug candidate was presented last week in Moscow at the 2nd Hematologists Congress of Russia.
According to Prof. Ann Turkina, M.D., a Russian specialist in chemotherapy of myeloproliferative diseases, “the coming of a new drug to treat chronic myeloleucosis is a timely development, as at the moment there are many patients resistant to currently available therapies.”